Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH)

NCT04187872 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT04187872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04187872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH)
Lead sponsor
University of Florida
Phase
Phase 1
Overall status
Terminated
Start date
January 10, 2020
Completion date
December 1, 2023
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, adult, cervical cancer, classical hodgkin lymphoma, esophageal cancer, gastric cancer, head and neck squamous cell cancer, hepatocellular carcinoma, melanoma, merkel cell carcinoma, microsatellite instability-high cancer, non-small cell lung carcinoma (nsclc), primary mediastinal large b-cell lymphoma, renal cell carcinoma (rcc), small-cell lung cancer, urothelial carcinoma